StocksFundsScreenerSectorsWatchlists
NTLA

NTLA - Intellia Therapeutics Inc Stock Price, Fair Value and News

21.58USD+0.26 (+1.22%)Market Closed

Market Summary

NTLA
USD21.58+0.26
Market Closed
1.22%

NTLA Stock Price

View Fullscreen

NTLA RSI Chart

NTLA Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-4.31

Price/Sales (Trailing)

57.17

EV/EBITDA

-40.19

Price/Free Cashflow

-5.08

NTLA Price/Sales (Trailing)

NTLA Profitability

EBT Margin

-186.20%

Return on Equity

-45.82%

Return on Assets

-36.99%

Free Cashflow Yield

-19.68%

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

36.3M

Rev. Growth (Yr)

-9.6%

Rev. Growth (Qtr)

-11.78%

NTLA Earnings

Earnings (TTM)

-481.2M

Earnings Growth (Yr)

-16.54%

Earnings Growth (Qtr)

-8.13%

Breaking Down NTLA Revenue

Last 7 days

-11.1%

Last 30 days

-22.3%

Last 90 days

-15.5%

Trailing 12 Months

-39.6%

How does NTLA drawdown profile look like?

NTLA Financial Health

Current Ratio

8.67

NTLA Investor Care

Shares Dilution (1Y)

9.19%

Diluted EPS (TTM)

-5.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202353.5M53.0M51.8M36.3M
202237.9M45.3M51.4M52.1M
202151.5M41.8M26.8M33.1M
202045.6M50.7M62.3M58.0M
201933.4M36.8M40.0M43.1M
201827.4M29.1M29.2M30.4M
201720.9M22.6M25.1M26.1M
20166.5M9.4M12.5M16.5M
20150006.0M

Tracking the Latest Insider Buys and Sells of Intellia Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 04, 2024
clark eliana
sold
-19,958
32.99
-605
evp, chief technical officer
Mar 04, 2024
basta james
sold
-75,778
32.99
-2,297
evp, general counsel
Mar 01, 2024
goddard glenn
acquired
-
-
28,628
evp, chief financial officer
Mar 01, 2024
hicks derek
acquired
-
-
29,393
evp, chief business officer
Mar 01, 2024
basta james
acquired
-
-
32,394
evp, general counsel
Mar 01, 2024
clark eliana
acquired
-
-
31,230
evp, chief technical officer
Mar 01, 2024
sepp-lorenzino laura
acquired
-
-
37,966
evp, chief scientific officer
Mar 01, 2024
leonard john m
acquired
-
-
113,586
president and ceo
Mar 01, 2024
lebwohl david
acquired
-
-
38,701
evp, chief medical officer
Jan 08, 2024
sepp-lorenzino laura
sold
-65,681
28.8711
-2,275
evp, chief scientific officer

1–10 of 50

Which funds bought or sold NTLA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
WOLFF WIESE MAGANA LLC
unchanged
-
-387
3,577
-%
Apr 18, 2024
Capital Advisors, Ltd. LLC
sold off
-100
-
-
-%
Apr 18, 2024
SteelPeak Wealth, LLC
new
-
228,581
228,581
0.01%
Apr 18, 2024
SJS Investment Consulting Inc.
unchanged
-
-84.00
771
-%
Apr 18, 2024
MV CAPITAL MANAGEMENT, INC.
new
-
166
166
-%
Apr 18, 2024
Allspring Global Investments Holdings, LLC
added
9.21
-3,636
244,674
-%
Apr 18, 2024
ARK Investment Management LLC
reduced
-3.71
-45,650,400
302,315,000
2.09%
Apr 17, 2024
BARRETT & COMPANY, INC.
unchanged
-
-894
8,253
-%
Apr 17, 2024
Cyndeo Wealth Partners, LLC
reduced
-0.15
-24,874
226,242
0.02%
Apr 16, 2024
Arlington Trust Co LLC
sold off
-100
-732
-
-%

1–10 of 43

Are Funds Buying or Selling NTLA?

Are funds buying NTLA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NTLA
No. of Funds

Unveiling Intellia Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.32%
8,347,449
SC 13G/A
Jan 29, 2024
ark investment management llc
12.74%
11,412,449
SC 13G/A
Jan 24, 2024
state street corp
5.29%
4,735,861
SC 13G/A
Jan 08, 2024
blackrock inc.
10.1%
9,010,695
SC 13G/A
Feb 10, 2023
ark investment management llc
11.20%
9,420,782
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.28%
7,810,226
SC 13G/A
Jan 25, 2023
blackrock inc.
8.7%
7,254,921
SC 13G
Feb 14, 2022
nikko asset management americas, inc.
3.70%
2,753,903
SC 13G/A
Feb 11, 2022
regeneron pharmaceuticals, inc.
4.98%
3,702,995
SC 13G/A

Recent SEC filings of Intellia Therapeutics Inc

View All Filings
Date Filed Form Type Document
Apr 16, 2024
PRE 14A
PRE 14A
Apr 15, 2024
8-K
Current Report
Mar 22, 2024
8-K
Current Report
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Intellia Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.7B
6.8B
-1.66% -28.18%
-8.22
5.66
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.2B
1.8B
-2.46% -28.84%
-41.3
9.94
76.23% 61.08%
16.7B
2.4B
4.57% -8.46%
99.75
6.91
15.42% 18.43%
11.8B
3.7B
-10.11% -29.11%
19.67
3.18
8.87% 75.42%
MID-CAP
5.7B
396.6M
-14.37% -42.33%
-10.84
14.45
425.83% 18.94%
4.4B
-
-13.59% 50.21%
-6.66
60.35
54.84% -34.79%
3.2B
270.6M
-13.81% -4.67%
-13.46
11.9
440.80% -27.84%
2.8B
726.4M
-9.91% -15.82%
-45.19
3.81
40.45% 71.62%
2.8B
240.7M
-20.67% -25.33%
-9.33
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-10.64% -8.42%
24.94
4.47
85.90% -14.05%
558.4M
983.7M
-17.39% -51.52%
-1.02
0.57
-50.36% 17.16%
409.4M
881.7K
-0.38% 387.14%
-9.18
466.16
-77.61% -5.33%
226.2M
4.9M
-10.29% -2.81%
-1.67
46.49
-54.97% 51.71%
6.0M
2.1M
59.81% 33.59%
-0.22
2.14
-13.45% 66.37%

Intellia Therapeutics Inc News

Latest updates
Nasdaq20 hours ago
The Motley Fool09 Mar 202408:00 am

Intellia Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-100.0%-11,992,00013,594,00012,606,00013,573,00013,266,00014,030,00011,252,00012,854,0007,204,0006,550,0006,445,0006,595,00022,220,00016,263,00012,916,00010,936,00010,616,00011,118,00010,433,0007,880,000
Costs and Expenses-3.6%137,975,000143,099,000145,928,000124,564,000123,660,000118,796,000112,331,000155,498,00093,269,00079,197,00075,567,00052,870,00048,994,00050,322,00049,297,00045,964,00040,707,00035,944,00038,578,00034,242,00028,626,000
  S&GA Expenses-1.4%28,994,00029,403,00030,652,00027,448,00023,626,00022,145,00022,132,00022,403,00022,108,00018,711,00016,683,00013,594,00010,763,00010,566,00011,526,00011,314,0008,976,0008,431,00013,118,00010,533,0008,708,000
  R&D Expenses-4.1%108,981,000113,696,000115,276,00097,116,000100,034,00096,651,00090,199,000133,095,00071,161,00060,486,00058,884,00039,276,00038,231,00039,756,00037,771,00034,650,00031,731,00027,513,00025,460,00023,709,00019,918,000
EBITDA Margin-41.6%-1.61-1.14-1.12-1.12-1.15-1.17-1.33-1.60-1.83-2.27-1.46-1.19---------
EBT Margin-42.7%-1.86-1.30-1.27-1.26-1.30-1.31-1.49-1.78-2.04-2.52-1.62-1.31---------
Net Income-8.1%-132,161,000-122,224,000-123,681,000-103,126,000-113,407,000-113,229,000-100,678,000-146,872,000-81,237,000-71,644,000-68,806,000-46,205,000-42,192,000-27,840,000-32,393,000-31,806,000-28,276,000-23,634,000-25,683,000-21,940,000-19,066,000
Net Income Margin-48.5%-13.27-8.93-8.55-8.05-9.10-8.60-8.83-9.73-8.10-8.54-4.43-2.88---------
Free Cashflow10.5%-94,574,000-105,713,000-94,624,000-113,160,000-93,781,000-82,763,000-89,071,000-81,230,000-57,519,000-69,560,000-55,919,000-54,788,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets4.6%1,3011,2431,3231,4181,5201,0841,1101,2031,2941,335672717676459491315334347352344347
  Current Assets11.7%9988939409641,217859895875769815549601617416446270289296307304325
    Cash Equivalents34.9%22716817229452414114813312333513014216018036281.0057.0038.0049.0047.0059.00
  Net PPE-3.1%33.0034.0033.0032.0028.0027.0026.0024.0021.0020.0019.0016.0016.0016.0016.0017.0018.0017.0017.0017.0017.00
Liabilities21.8%251206--285----------------
  Current Liabilities25.3%11592.0010010312713112412612698.0074.0061.0064.0056.0059.0035.0036.0038.0038.0039.0041.00
Shareholder's Equity1.2%1,0501,0371,1051,1911,2368258819541,0401,107495546527330352248270276277264278
  Retained Earnings-8.7%-1,658-1,526-1,403-1,280-1,177-1,063-950-849-703-621-550-481-435-392-365-332-300-272-248-223-201
  Additional Paid-In Capital5.6%2,7112,5672,5132,4742,4201,8981,8411,8121,7461,7291,0451,027962723717580570548526488479
Shares Outstanding4.4%93.0089.0088.0088.0087.0076.0075.0075.0071.0070.0068.0067.00---------
Float---3,565---3,889---10,926---1,183---741--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations8.2%-93,054-101,381-90,323-109,328-89,869-78,526-85,091-79,801-54,651-65,022-52,981-52,376-40,226-28,55857,417-38,545-28,662-25,448-27,677-21,453-8,538
  Share Based Compensation-0.9%35,04335,35236,40027,25524,62625,21523,06818,49114,56115,41010,6146,4245,5825,4004,7644,1573,0163,0794,4044,5923,582
Cashflow From Investing-42.2%45,93979,500-34,538-122,248-30,15247,64395,34547,473-159,115-399,38133,260-25,542-210,918-153,98092,96357,44827,884-31,65223,2495,695-256,016
Cashflow From Financing457.4%106,48419,1022,5162,221505,76323,9775,89547,3202,280668,6807,13358,595234,093597132,2254,86419,56446,4006,4713,99930,162

NTLA Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Collaboration revenue$ 36,275$ 52,121$ 33,053
Type of Revenue [Extensible List]us-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMember
Operating expenses:   
Research and development$ 435,069$ 419,979$ 229,807
General and administrative116,49790,30671,096
Total operating expenses551,566510,285300,903
Operating loss(515,291)(458,164)(267,850)
Other income (expense), net:   
Interest income49,8328,5421,283
Loss from equity method investments(15,633)(11,079)(1,325)
Change in fair value of contingent consideration(100)(13,485)0
Total other income (expense), net34,099(16,022)(42)
Net loss$ (481,192)$ (474,186)$ (267,892)
Net Loss Per Share, Basic$ (5.42)$ (6.16)$ (3.78)
Net Loss Per Share, Diluted$ (5.42)$ (6.16)$ (3.78)
Weighted average shares outstanding, basic88,77076,97270,894
Weighted average shares outstanding, diluted88,77076,97270,894
Other comprehensive loss:   
Unrealized gain (loss) on marketable securities$ 3,635$ (1,637)$ (2,126)
Other comprehensive gain (loss) from equity method investment1,568(3,192)(507)
Comprehensive loss$ (475,989)$ (479,015)$ (270,525)

NTLA Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 226,748$ 523,506
Marketable securities685,475669,116
Accounts receivable ($0.2 million and $0.3 million, respectively,from related party)36,4563,768
Prepaid expenses and other current assets49,65120,407
Total current assets998,3301,216,797
Marketable securities - noncurrent99,86469,338
Property and equipment, net32,76027,921
Operating lease right-of-use assets115,375133,076
Equity method investment11,76532,455
Investments and other assets42,88340,527
Total Assets1,300,9771,520,114
Current Liabilities:  
Accounts payable7,4525,154
Accrued expenses ($1.0 million and $1.6 million, respectively, from related party)67,01760,876
Current portion of operating lease liability18,59916,685
Current portion of deferred revenue ($0 and $19.9 million, respectively,from related party)22,14043,839
Total current liabilities115,208126,554
Deferred revenue, net of current portion38,85319,932
Long-term operating lease liability96,747114,018
Contingent consideration liability024,026
Total liabilities250,808284,530
Commitments and contingencies (Note 8)
Stockholders’ Equity:  
Common stock, $0.0001 par value; 240,000,000 and 120,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively;92,997,158 and 87,103,007 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively99
Additional paid-in capital2,710,7972,420,223
Accumulated other comprehensive loss(2,258)(7,461)
Accumulated deficit(1,658,379)(1,177,187)
Total stockholders’ equity1,050,1691,235,584
Total Liabilities and Stockholders’ Equity$ 1,300,977$ 1,520,114
NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEintelliatx.com
 INDUSTRYBiotechnology
 EMPLOYEES598

Intellia Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Intellia Therapeutics Inc? What does NTLA stand for in stocks?

NTLA is the stock ticker symbol of Intellia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intellia Therapeutics Inc (NTLA)?

As of Fri Apr 19 2024, market cap of Intellia Therapeutics Inc is 2.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTLA stock?

You can check NTLA's fair value in chart for subscribers.

What is the fair value of NTLA stock?

You can check NTLA's fair value in chart for subscribers. The fair value of Intellia Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intellia Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NTLA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intellia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NTLA is over valued or under valued. Whether Intellia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Intellia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTLA.

What is Intellia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, NTLA's PE ratio (Price to Earnings) is -4.31 and Price to Sales (PS) ratio is 57.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTLA PE ratio will change depending on the future growth rate expectations of investors.